Ann: IMM presents positive interim phase 2 TACTI-002 data at SITC, page-20

If a scientist looks at the results here, these are great results, yet small cohort and not gonna be strong enough to speak to the new ultimate patient care.
However, are these results good enough to support a further bigger trial and warrant a bright future for IMM? Of course, that is exactly what happen at the moment.
To me, the first large cohort trial by IMM due for announce Q1 2020, is the real key for sealing the deal. That will be the fundamental ground for this company to get FDA approval and becomes similar like the route of PD-1 production couple years ago.